678 related articles for article (PubMed ID: 16412990)
21. Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism.
Fantin M; Auberson YP; Morari M
J Neurochem; 2008 Jul; 106(2):957-68. PubMed ID: 18435828
[TBL] [Abstract][Full Text] [Related]
22. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
[TBL] [Abstract][Full Text] [Related]
24. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
[TBL] [Abstract][Full Text] [Related]
25. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen.
Romero J; Berrendero F; Pérez-Rosado A; Manzanares J; Rojo A; Fernández-Ruiz JJ; de Yebenes JG; Ramos JA
Life Sci; 2000; 66(6):485-94. PubMed ID: 10794065
[TBL] [Abstract][Full Text] [Related]
26. In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease.
Casteels C; Lauwers E; Baitar A; Bormans G; Baekelandt V; Van Laere K
Brain Res; 2010 Feb; 1316():153-62. PubMed ID: 20026090
[TBL] [Abstract][Full Text] [Related]
27. The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently.
Polissidis A; Galanopoulos A; Naxakis G; Papahatjis D; Papadopoulou-Daifoti Z; Antoniou K
Int J Neuropsychopharmacol; 2013 Mar; 16(2):393-403. PubMed ID: 22391102
[TBL] [Abstract][Full Text] [Related]
28. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
[TBL] [Abstract][Full Text] [Related]
29. GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Petri D; Pum M; Vesper J; Huston JP; Schnitzler A
Behav Brain Res; 2013 Sep; 252():58-67. PubMed ID: 23727148
[TBL] [Abstract][Full Text] [Related]
30. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
31. Effects of calpain inhibition on dopaminergic markers and motor function following intrastriatal 6-hydroxydopamine administration in rats.
Grant RJ; Sellings LH; Crocker SJ; Melloni E; Park DS; Clarke PB
Neuroscience; 2009 Jan; 158(2):558-69. PubMed ID: 19007862
[TBL] [Abstract][Full Text] [Related]
32. Neuronal firing activity and gene expression changes in the subthalamic nucleus after transplantation of dopamine neurons in hemiparkinsonian rats.
Rumpel R; Alam M; Klein A; Özer M; Wesemann M; Jin X; Krauss JK; Schwabe K; Ratzka A; Grothe C
Neurobiol Dis; 2013 Nov; 59():230-43. PubMed ID: 23938762
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease.
Cerri S; Levandis G; Ambrosi G; Montepeloso E; Antoninetti GF; Franco R; Lanciego JL; Baqi Y; Müller CE; Pinna A; Blandini F; Armentero MT
J Neuropathol Exp Neurol; 2014 May; 73(5):414-24. PubMed ID: 24709676
[TBL] [Abstract][Full Text] [Related]
34. Reversal effect of simvastatin on the decrease in cannabinoid receptor 1 density in 6-hydroxydopamine lesioned rat brains.
Mackovski N; Liao J; Weng R; Wei X; Wang R; Chen Z; Liu X; Yu Y; Meyer BJ; Xia Y; Deng C; Huang XF; Wang Q
Life Sci; 2016 Jun; 155():123-32. PubMed ID: 27155397
[TBL] [Abstract][Full Text] [Related]
35. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study.
Mailleux P; Vanderhaeghen JJ
J Neurochem; 1993 Nov; 61(5):1705-12. PubMed ID: 7901331
[TBL] [Abstract][Full Text] [Related]
36. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Han B; Jin HJ; Song MY; Wang T; Zhao H
Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
[TBL] [Abstract][Full Text] [Related]
37. Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta.
Freestone PS; Guatteo E; Piscitelli F; di Marzo V; Lipski J; Mercuri NB
Neuropharmacology; 2014 Apr; 79():467-75. PubMed ID: 24334069
[TBL] [Abstract][Full Text] [Related]
38. Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease.
Andrzejewski K; Budzińska K; Zaremba M; Kaczyńska K
Neuroscience; 2016 Mar; 316():192-200. PubMed ID: 26705738
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
[TBL] [Abstract][Full Text] [Related]
40. Significance of cannabinoid CB1 receptors in improgan antinociception.
Gehani NC; Nalwalk JW; Razdan RK; Martin BR; Sun X; Wentland M; Abood ME; Hough LB
J Pain; 2007 Nov; 8(11):850-60. PubMed ID: 17644043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
